Last reviewed · How we verify

NCT03212261

Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma

Completed NA Results posted Last updated 10 November 2021
What this trial tests

NA trial testing 3RP-Lymphoma in Lymphoma in 37 participants. Completed in 24 September 2018.

Timeline
3 August 2017
Primary endpoint
30 June 2018
24 September 2018

Quick facts

Lead sponsorMassachusetts General Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment37
Start date3 August 2017
Primary completion30 June 2018
Estimated completion24 September 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Massachusetts General Hospital

Who can join

Adults 18 to 64, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Program Feasibility: Number of Participants Who Completed at Least 75% of the Treatment Sessions Primary · 1 month after completing the 3RP-Lymphoma program

The investigators will evaluate program feasibility by examining rates of treatment completion. Participants who complete at least 75% of the treatment sessions will be identified as treatment completers.

GroupValue95% CI
3RP-Lymphoma20
Number of Participants Who Found the 3RP Program Acceptable Primary · 1 month after completing the 3RP-Lymphoma program

Acceptability will be assessed at the one-month follow up data collection period with five questions on the 3RP acceptability questionnaire rated on a 4-point Likert scale (1=not at all to 4=very much); higher scores mean higher levels of acceptability.

Enjoyable
GroupValue95% CI
3RP-Lymphoma21
3RP-Lymphoma0
Helpful
GroupValue95% CI
3RP-Lymphoma21
3RP-Lymphoma0
Relevant
GroupValue95% CI
3RP-Lymphoma21
3RP-Lymphoma0
Convenient
GroupValue95% CI
3RP-Lymphoma19
3RP-Lymphoma2
Somewhat/Very likely to do RR in the future
GroupValue95% CI
3RP-Lymphoma21
3RP-Lymphoma0
Number of Participants Who Were Eligible to Provide and Provided Hair Cortisol Samples Secondary · 1 month after completing the 3RP-Lymphoma program

The investigators will explore the feasibility and acceptability of collecting hair samples to examine levels of cortisol, a stress biomarker.

Total eligible to provide a sample
GroupValue95% CI
3RP-Lymphoma20
Total provided sample based on # eligible
GroupValue95% CI
3RP-Lymphoma14

Sponsor's own description

The Relaxation Response Resiliency Program (3RP) was developed by researchers at the MGH Benson-Henry Institute for Mind Body Medicine; This program has recently been adapted to target the needs of individuals who have completed treatment for lymphoma (3RP-Lymphoma).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A virtual resiliency program for lymphoma survivors: helping survivors cope with post-treatment challenges.
    Perez GK, Walsh EA, Quain K, Abramson JS, et al · · 2021 · cited 11× · PMID 33251861 · DOI 10.1080/08870446.2020.1849699

Verify or expand the search:

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

Other Massachusetts General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03212261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing